Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSerco Regulatory News (SRP)

Share Price Information for Serco (SRP)

Share Price is delayed by 15 minutes
Get Live Data
253.60    -0.20 (-0.08%)
Bid:
254.00
Ask:
254.80
Spread: 0.80 (0.315%)
Market Cap: £2.51b
SRP Live PriceLast checked at - London Stock Exchange

Intraday Serco Share Chart

Trading update

15 Nov 2021 07:00

RNS Number : 3106S
Serco Group PLC
15 November 2021
 

Trading update

15 November 2021

 

Serco today provides an update to 2021 guidance, following stronger than expected recent trading.

 

Recent trading

Trading has been stronger than we expected in recent months, and we now expect revenue to be around £4.4bn, and Underlying Trading Profit to be not less than £225m. Several factors have driven this improved performance, most of which are unlikely to repeat. First, in the UK and Australia, volumes of work related to Covid-19 support to governments have been higher, and have continued for longer, than we anticipated. Second, a number of contracts across the business have performed better than we expected, notably immigration-related contracts in the UK and Australia, and our healthcare insurance eligibility services contract (CMS) in the United States, where the decision of the Biden administration to extend the open enrolment period has resulted in additional volumes. Finally, a number of commercial discussions that we had expected to complete in 2022 are now anticipated to be finalised in the current financial year. Cash generation has also remained strong.

 

Recognising the extraordinary efforts of our colleagues around the world and the difficulties experienced by many as a consequence of the pandemic, we will be making an ex-gratia payment to around 52,000 employees, as we did in 2020, and in addition we will be making a significant one-off commitment to our recently established Serco People Fund. The fund provides cash and other support to colleagues who would benefit from a little extra help at this difficult time. Together, these initiatives will cost the company around £10m in the current year.

 

Our revised guidance for 2021 is set out below:

 

2020Actual

2021Prior guidance

2021Latest guidance

Revenue

£3.9bn

~£4.3bn

~£4.4bn

Organic sales growth

16%

~6%

~10%

Underlying Trading Profit

£163m

~£200m

≥£225m

Net Finance Costs

£26m

~£28m

~£26m

Underlying effective tax rate

23%

~25%

~25%

Free Cash Flow

£135m

~£120m

~£150m

Adjusted Net Debt

£58m

~£250m

~£220m

Notes: The guidance uses an average GBP:USD exchange rate of 1.38 in 2021 and GBP:AUD of 1.83.

 

Outlook for 2022

We are yet to complete our budget process for 2022, and we will be working over the coming weeks to finalise individual budgets and gain Board approval. We expect to be ready to give our usual detailed guidance for the year ahead in conjunction with our Capital Markets Day on 2 December. At this point, we do not expect the guidance for revenue and trading profit for 2022 to be materially different to current analysts' consensus*. We expect 2022 to see much lower demand for Covid-19 related services, partially offset by the impact of new work secured in 2021 and growth in our core non-Covid-19 related business.

 

*Serco-compiled consensus is £4.2bn of revenue and £196m of Underlying Trading Profit. Bloomberg consensus is £4.2bn of revenue and £192m of Underlying Trading Profit as at 12 November 2021.

 

This announcement contains inside information.

 

Ends

 

For further information please contact:

Paul Checketts, Head of Investor Relations, tel: +44 (0) 7718 195 074 or email: paul.checketts@serco.com

Marcus De Ville, Head of Media Relations, tel: +44 (0) 7738 898 550 or email: marcus.deville@serco.com

 

About Serco

Serco is a leading provider of public services. Our customers are governments or others operating in the public sector. We gain scale, expertise and diversification by operating internationally across five sectors and four geographies: Defence, Justice & Immigration, Transport, Health and Citizen Services, delivered in UK & Europe, North America, Asia Pacific and the Middle East.

 

More information can be found at www.serco.com

 

LEI: 549300PT2CIHYN5GWJ21

 

Forward looking statements

This announcement contains statements which are, or may be deemed to be, "forward-looking statements" which are prospective in nature. All statements other than statements of historical fact are forward-looking statements. Generally, words such as "expect", "anticipate", "may", "could", "should", "will", "aspire", "aim", "plan", "target", "goal", "ambition", "intend" and similar expressions identify forward looking-statements. By their nature, these forward-looking statements are subject to a number of known and unknown risks, uncertainties and contingencies, and actual results and events could differ materially from those currently being anticipated as reflected in such statements. Factors which may cause future outcomes to differ from those foreseen or implied in forward-looking statements include, but are not limited to: general economic conditions and business conditions in Serco's markets; contracts awarded to Serco; customers' acceptance of Serco's products and services; operational problems; the actions of competitors, trading partners, creditors, rating agencies and others; the success or otherwise of partnering; changes in laws and governmental regulations; regulatory or legal actions, including the types of enforcement action pursued and the nature of remedies sought or imposed; the receipt of relevant third party and/or regulatory approvals; exchange rate fluctuations; the development and use of new technology; changes in public expectations and other changes to business conditions; wars and acts of terrorism; cyber-attacks; and pandemics, epidemics or natural disasters. Many of these factors are beyond Serco's control or influence. These forward-looking statements speak only as of the date of this presentation and have not been audited or otherwise independently verified. Past performance should not be taken as an indication or guarantee of future results and no representation or warranty, express or implied, is made regarding future performance. Except as required by any applicable law or regulation, Serco expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained in this presentation to reflect any change in Serco's expectations or any change in events, conditions or circumstances on which any such statement is based after the date of this presentation, or to keep current any other information contained in this presentation. Accordingly, undue reliance should not be placed on the forward-looking statements.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTEAFFLFAXFFAA
Date   Source Headline
12th Apr 20247:00 amRNSTransaction in Own Shares
11th Apr 20243:47 pmRNSDirector/PDMR Shareholding
11th Apr 20247:00 amRNSTransaction in Own Shares
10th Apr 20246:03 pmRNSDirector/PDMR Shareholding
10th Apr 20247:00 amRNSTransaction in Own Shares
9th Apr 20247:00 amRNSTransaction in Own Shares
8th Apr 20247:00 amRNSTransaction in Own Shares
5th Apr 20247:00 amRNSTransaction in Own Shares
4th Apr 20247:00 amRNSTransaction in Own Shares
3rd Apr 20247:00 amRNSTransaction in Own Shares
2nd Apr 20247:00 amRNSDirector/PDMR Shareholding
28th Mar 20245:33 pmRNSTransaction in Own Shares and Total Voting Rights
28th Mar 20247:00 amRNSTransaction in Own Shares
27th Mar 20247:00 amRNSTransaction in Own Shares
26th Mar 20247:00 amRNSTransaction in Own Shares
25th Mar 20247:00 amRNSTransaction in Own Shares
22nd Mar 20247:00 amRNSTransaction in Own Shares
21st Mar 20247:00 amRNSTransaction in Own Shares
20th Mar 202410:00 amRNSPublication of the 2023 ARA and 2024 Notice of AGM
20th Mar 20247:00 amRNSTransaction in Own Shares
19th Mar 20247:00 amRNSTransaction in Own Shares
18th Mar 20247:00 amRNSTransaction in Own Shares
15th Mar 20247:00 amRNSTransaction in Own Shares
14th Mar 20247:00 amRNSTransaction in Own Shares
13th Mar 20247:00 amRNSTransaction in Own Shares
12th Mar 20247:00 amRNSTransaction in Own Shares
11th Mar 20247:00 amRNSTransaction in Own Shares
8th Mar 20247:00 amRNSTransaction in Own Shares
7th Mar 20247:00 amRNSTransaction in Own Shares
6th Mar 20247:00 amRNSTransaction in Own Shares
5th Mar 20247:00 amRNSShare Repurchase Programme
4th Mar 20247:00 amRNSSerco completes acquisition of European Homecare
1st Mar 20245:43 pmRNSAnnual Financial Report
29th Feb 20247:00 amRNS2023 Final Results
2nd Feb 20244:33 pmRNSHolding(s) in Company
29th Jan 20244:46 pmRNSHolding(s) in Company
22nd Jan 202411:36 amRNSHolding(s) in Company
29th Dec 202310:00 amRNSTotal Voting Rights
27th Dec 20232:30 pmRNSHolding(s) in Company
14th Dec 20237:00 amRNSAcquisition of leading German immigration business
14th Dec 20237:00 amRNSPre-close trading update
11th Dec 202310:31 amRNSCancellation of Treasury Shares
6th Dec 20231:03 pmRNSDirector Declaration
5th Dec 202312:40 pmRNSHolding(s) in Company
27th Nov 20235:45 pmRNSBlock Listing Application
8th Nov 20237:00 amRNSSerco wins £200m electronic monitoring contract
25th Oct 20237:00 amRNSSerco appoints new CEO in Asia Pacific
20th Oct 20232:02 pmRNSHolding(s) in Company
17th Oct 20237:00 amRNSSerco wins new £350m contract
10th Oct 202312:27 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.